Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) Director Howard Lee sold 37,994 shares of the firm’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $20.65, for a total transaction of $784,576.10. Following the transaction, the director now directly owns 134,527 shares of the company’s stock, valued at $2,777,982.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Howard Lee also recently made the following trade(s):

  • On Thursday, September 1st, Howard Lee sold 10,381 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $18.78, for a total transaction of $194,955.18.

Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) opened at 21.55 on Friday. The company has a market cap of $991.80 million, a price-to-earnings ratio of 47.05 and a beta of 1.86. Amphastar Pharmaceuticals Inc. has a 12-month low of $10.50 and a 12-month high of $21.58. The stock has a 50 day moving average of $18.96 and a 200 day moving average of $17.32.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Tuesday, November 8th. The company reported $0.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.11. The company earned $64.20 million during the quarter, compared to analysts’ expectations of $65.12 million. Amphastar Pharmaceuticals had a net margin of 7.75% and a return on equity of 6.79%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.01) earnings per share. Equities research analysts predict that Amphastar Pharmaceuticals Inc. will post $0.47 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

A number of equities analysts have commented on AMPH shares. Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research note on Tuesday, October 11th. Needham & Company LLC lifted their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Jefferies Group lifted their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. BMO Capital Markets reissued a “hold” rating and issued a $17.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Tuesday, August 9th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $23.00 price objective (up from $22.00) on shares of Amphastar Pharmaceuticals in a research note on Wednesday, September 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Amphastar Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $20.17.

A number of institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors boosted its position in Amphastar Pharmaceuticals by 105.3% in the third quarter. BlackRock Fund Advisors now owns 3,085,037 shares of the company’s stock worth $58,523,000 after buying an additional 1,581,978 shares in the last quarter. Acadian Asset Management LLC boosted its position in Amphastar Pharmaceuticals by 92.3% in the third quarter. Acadian Asset Management LLC now owns 1,573,986 shares of the company’s stock worth $29,858,000 after buying an additional 755,366 shares in the last quarter. Prudential Financial Inc. bought a new position in Amphastar Pharmaceuticals during the third quarter worth $7,508,000. Principal Financial Group Inc. bought a new position in Amphastar Pharmaceuticals during the third quarter worth $4,875,000. Finally, BlackRock Institutional Trust Company N.A. boosted its position in Amphastar Pharmaceuticals by 45.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 824,113 shares of the company’s stock worth $13,285,000 after buying an additional 256,940 shares in the last quarter. Institutional investors own 44.18% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

5 Day Chart for NASDAQ:AMPH

Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.